Clinical Trials Logo

Clinical Trial Summary

An effectiveness-implementation sequential explanatory hybrid design type 2 was performed in two rural communities of Colombia. A quasi-experimental study with historical control (standard of care) was designed to estimate the effectiveness of community-based intervention using the Guaral+ST mobile application (app). Three implementation outcomes were evaluated: acceptability and usability by qualitative methods, and fidelity by quantitative methods


Clinical Trial Description

An effectiveness-implementation sequential explanatory hybrid design type 2 using mixed methods was performed in 2020 and 2021 in two study sites: Pueblo Rico, Risaralda, and Rovira, Tolima. A quasi-experimental study with historical control (standard of care) was designed to evaluate the effectiveness of the community-based intervention supported by mHealth, in terms of monitoring of treatment of patients with cutaneous leishmaniasis. The effectiveness indicators i. number of follow-up contacts, ii. Adherence to treatment, iii. adverse drug reactions, and iv. the therapeutic response were compared between the intervention and control groups. After the effectiveness evaluation was completed, three outcomes were assessed to inform the implementation of the community-based use of the app: acceptability, usability, and fidelity. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05533736
Study type Interventional
Source Centro Internacional de Entrenamiento e Investigaciones Médicas
Contact
Status Completed
Phase N/A
Start date March 1, 2020
Completion date December 1, 2021

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06011343 - Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis Phase 2/Phase 3
Completed NCT06449040 - Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly Phase 1/Phase 2
Completed NCT06000514 - Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis. Phase 1/Phase 2
Completed NCT03829917 - Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis Phase 2/Phase 3